Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: An extended-release, abuse-deterrent formulation

Ernest A. Kopecky, PhD, MBA; Alison B. Fleming, PhD; Patrick K. Noonan, PhD; Ravi K. Varanasi, MPharm; Michael Grima, BS; Said Saim, PhD; Stephen P. Mayock, BS

doi:10.5055/jom.2014.0211

Authors

Ernest A. Kopecky, PhD, MBA Collegium Pharmaceutical, Inc., Canton, Massachusetts
Alison B. Fleming, PhD Collegium Pharmaceutical, Inc., Canton, Massachusetts
Patrick K. Noonan, PhD PK Noonan & Associates, Williamsburg, Virginia
Ravi K. Varanasi, MPharm Collegium Pharmaceutical, Inc., Canton, Massachusetts
Michael Grima, BS Collegium Pharmaceutical, Inc., Canton, Massachusetts
Said Saim, PhD Collegium Pharmaceutical, Inc., Canton, Massachusetts
Stephen P. Mayock, BS Collegium Pharmaceutical, Inc., Canton, Massachusetts

DOI:

https://doi.org/10.5055/jom.2014.0211

Keywords:

DETERx, , oxycodone, physical, manipulation, abuse-deterrent, pain

Abstract

Objective: In vitro: To assess the effect of common crushing techniques on particle size reduction (PSR) and in vitro drug-release kinetics of oxycodone DETERx® (herein DETERx) and of a commercially available oxycodone extended-release (ER) tablet. In vivo: To evaluate the impact of the most effective manipulation method identified in the in vitro study and the effect of chewing on the pharmacokinetics (PK) of DETERx relative to oxycodone solution.

Design: In vitro: Mechanical manipulation of dosage forms using common household utensils. In vivo: Open-label, randomized, active-controlled, crossover PK study.

Subjects: In vivo: Forty-four healthy male and female volunteers.

Methods: In vitro: DETERx capsule contents and marketed comparator tablets were subjected to manipulation (crushing) using 10 different household utensils. Particle size and dissolution analysis were conducted. In vivo: Subjects were randomly assigned to receive DETERx 40-mg capsules intact, crushed, or chewed or oxycodone solution. Serial blood samples were drawn for PK assessment.

Results: In vitro: The utensils used to manipulate DETERx capsule contents were either ineffective in reducing the particle size or produced only a small change in the median particle size and dissolution rate relative to the marketed comparator. In vivo: DETERx intact capsules provided significantly lower Cmax and longer Tmax values than oxycodone solution. Manipulation of DETERx by crushing (using the most effective method established in vitro) or chewing resulted in bioequivalent plasma concentration-time profiles to the intact dosage form.

Conclusion: These mechanical manipulation and PK studies demonstrated that DETERx beads retained their ER properties after mechanical tampering and chewing by study subjects.

References

Passik SD, Hays L, Eisner N, et al.: Psychiatrie and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006; 20(2): 5-13. DOI: https://doi.org/10.1080/J354v20n02_03

Katz N, Dart RC, Bailey E, et al.: Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37(4): 205-217. DOI: https://doi.org/10.3109/00952990.2011.569623

Abuse S: Mental Health Services Administration (SAMHSA), 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2012.

Substance Abuse and Mental Health Services Administration: Drug abuse warning network, 2010: national estimates of drug-related emergency department visits. DHHS Publication No. SMA 12-4733, DAWN Series D-38. 2012. Available at http://samhsa.gov/data/2k13/DAWN2k10ED/DAWN2k10ED.htm. Accessed May 22, 2013.

Bhamb B, Brown D, Hariharan J, et al.: Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006; 22(9): 1859-1865. DOI: https://doi.org/10.1185/030079906X132398

Upshur CC, Luckmann RS, Savageau JA: Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006; 21(6): 652-655. DOI: https://doi.org/10.1111/j.1525-1497.2006.00412.x

US Food and Drug Administration: FDA approves abuse-deterrent labeling for reformulated OxyContin. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.html. Accessed June 4, 2013.

Romach M, Schoedel K, Sellers E: Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013; 130(1): 13-23. DOI: https://doi.org/10.1016/j.drugalcdep.2012.12.028

Stanos SP, Bruckenthal P, Barkin RL (eds.): Strategies to reduce the tampering and subsequent abuse of long-acting opioids: Potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering. Mayo Clinic Proceedings, 2012. Elsevier. DOI: https://doi.org/10.1016/j.mayocp.2012.02.022

Butler SF, Cassidy TA, Chilcoat H, et al.: Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013; 14(4): 351-358. DOI: https://doi.org/10.1016/j.jpain.2012.08.008

Katz N, Fernandez K, Chang A, et al.: Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008; 24(6): 528-535. DOI: https://doi.org/10.1097/AJP.0b013e318167a087

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for industry: Abuse-deterrent opioids—Evaluation and labeling. January 2013. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed June 4, 2013.

Mayock S: Report #COL-003-12-002R, 2012. Data on file. Canton, MA: Collegium Pharmaceutical, Inc.

Oxycodone Hydrochloride Extended-Release Tablets. United States Pharmacopeia and National Formulary (USP 32-NF 27). Rockville, MD: United States Pharmacopeia Convention, 2010: 3167.

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for industry: SUPAC-MR: modified release solid oral dosage forms. September 1997. Available at http://www.fda.gov/downloads/Drugs/Guidances/UMC070640.pdf. Accessed July 23, 2013.

Data on File, Collegium Pharmaceutical, Inc., 2014.

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products—General considerations. March 2003. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070124.pdf. Accessed April 4, 2014.

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Guidance for industry: Food effect bioavailability and fed bioequivalence studies. December 2002. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070241.pdf. Accessed June 4, 2013.

Data on file: Study ZZ37950-01, Bioanalytical Method SOP for the Determination of Oxycodone in Human Plasma (EDTA), 2013. Lincoln, NE: Celerion.

Cone EJ, Giordano J, Weingarten B: An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013; 131(1): 100-105. DOI: https://doi.org/10.1016/j.drugalcdep.2012.12.006

Benziger DP, Kaiko RF, Miotto JB, et al.: Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci. 1996; 85(4): 407-410. DOI: https://doi.org/10.1021/js950403a

Moorman-Li R, Motycka CA, Inge LD, et al.: A review of abuse-deterrent opioids for chronic nonmalignant pain. Pharm Ther. 2012; 37(7): 412.

Harris S, Colucci S, Perrino P, et al.: Effects of various tampering methods on exposure to oxycodone in healthy subjects. Poster No. 78. Presented at the 74th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Springs, CA, 9–14 June, 2012.

US Food and Drug Administration: Center for Drug Evaluation and Research (CDER). Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety & Risk Management Advisory Committee. Meeting documents and slides. November 13, 2008. Available at http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4395s1-03-FDA-Ji.ppt. Accessed June 3, 2013.

Center for Drug Evaluation and Research (CDER): Clinical pharmacology and biopharmaceutics review(s). Application No. 201655. June 13, 2011. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201655Orig1s000ClinPharmR.pdf. Accessed Jun 5, 2013.

Pergolizzi JV Jr, Taylor R Jr, Nalamachu S, et al.: Challenges of treating patients with chronic pain with dysphagia (CPD): Physician and patient perspectives. Curr Med Res Opin. 2014; 30(2): 191-202. DOI: https://doi.org/10.1185/03007995.2013.854197

Stubbs J, Haw C, Dickens G: Dose form modification—A common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr. 2008; 20(03): 616-627. DOI: https://doi.org/10.1017/S1041610207006047